(Q38735562)

6 September 2017

title

Pridopidine for the treatment of Huntington's disease (English)

1 reference

6 September 2017

0 references

Kathleen M Shannon

1

1 reference

6 September 2017

language of work or name

English

0 references

publication date

16 February 2016

1 reference

Expert Opinion on Investigational Drugs

6 September 2017

published in

1 reference

6 September 2017

volume

25

1 reference

6 September 2017

issue

4

1 reference

6 September 2017

page(s)

485-492

1 reference

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Determinants of functional disability in Huntington's disease: role of cognitive and motor dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

A review of cognition in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Cognitive and psychiatric aspects of Huntington disease contribute to functional capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

The Prevalence of Juvenile Huntington's Disease: A Review of the Literature and Meta-Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Dopamine and Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Levodopa and presymptomatic detection of Huntington's disease--eight-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Levodopa in the presymptomatic diagnosis of Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Pharmacological management of Huntington's disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

An evidence-based approach in the treatment of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Update on Huntington's disease: advances in care and emerging therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Current Pharmacological Management in Juvenile Huntington's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Huntington's disease: clinical correlates of disability and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Triheptanoin improves brain energy metabolism in patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Sigma-1 receptor is involved in degradation of intranuclear inclusions in a cellular model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

In vivo pharmacology of the dopaminergic stabilizer pridopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

One-year safety and tolerability profile of pridopidine in patients with Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2016.1153627

10.1517/13543784.2016.1153627

21 January 2018

Identifiers

DOI

1 reference

6 September 2017

1 reference